RESUMO
ESA-10 is an embryonic antigen expressed by tumor cells. A method to detect the antigen in the blood based on alterations in the erythrocyte sedimentation rate that occur when antiserum to ESA-10 is bound to the antigen in blood was devised and used here to determine the sensitivity and predictive value of the test in patients with biopsy proven non-hematologic malignancies, and in normal control subjects. The test was positive in 22 of 24 cancer patients tested, and negative in 30 of 35 control subjects. Of the five positive control subjects, one female had recently given birth and was lactating. Another control subject was recently diagnosed with prostate cancer, just months after having participated in this study. Therefore, this tumor marker test (Turtest(®)) had a sensitivity of 91.7% and a positive predictive value of 81.5% in patients with biopsy proven cancer, and a specificity and negative predictive value in control subjects of 88.2 and 93.8%, respectively, if the control subject who subsequently developed prostate cancer is removed from the control group. Therefore, this simple test has potential as a clinically useful tumor marker with sensitivity and specificity equal to or greater than other commercially available tumor markers and should be explored further in larger studies.
Assuntos
Antígenos de Neoplasias/sangue , Antígenos de Superfície/sangue , Neoplasias/sangue , Neoplasias/diagnóstico , Adulto , Idoso , Idoso de 80 Anos ou mais , Animais , Estudos de Casos e Controles , Ensaio de Imunoadsorção Enzimática , Feminino , Humanos , Masculino , Camundongos , Camundongos Endogâmicos CBA , Pessoa de Meia-Idade , Prognóstico , Sensibilidade e EspecificidadeAssuntos
Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem , Interleucina-2/administração & dosagem , Linfoma de Células B/terapia , Derrame Pleural Maligno/terapia , Anticorpos Monoclonais/administração & dosagem , Anticorpos Monoclonais/efeitos adversos , Anticorpos Monoclonais Murinos , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Ciclofosfamida/administração & dosagem , Ciclofosfamida/efeitos adversos , Humanos , Linfoma de Células B/diagnóstico por imagem , Masculino , Pessoa de Meia-Idade , Derrame Pleural Maligno/diagnóstico por imagem , Prednisolona/administração & dosagem , Prednisolona/efeitos adversos , Radiografia , Rituximab , Vincristina/administração & dosagem , Vincristina/efeitos adversosRESUMO
Granulocyte colony-stimulating factor (G-CSF) is a recombinant human glycoprotein that promotes proliferation and differentiation of granulocytic-committed progenitors. It is commonly used to treat neutropenia and is generally well tolerated. Occurrences of rare but serious adverse events in association with the use of G-CSF have been described. We report the case of a 54-year-old male with squamous cell carcinoma of the lung who developed abdominal aortitis following the use of G-CSF. Other possible aetiological conditions were excluded based on laboratory and radiological evaluations. To our knowledge, this represents the second case report demonstrating an association between aortitis and the use of G-CSF.
